SCHEMBL3373741

SCHEMBL3373741

O=C(O)CN1c2ccccc2C(O)c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.53
CA9 Q16790 1/20 0.53
APEX1 P27695 1/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HDAC9 Q9UKV0 1/20 0.42
HDAC5 Q9UQL6 1/20 0.42
CDC25A P30304 1/20 0.41
KDM4E B2RXH2 1/20 0.40
EGFR P00533 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19673997 0.87 CA12 (0.49) CA12CA9APEX1MEN1KMT2A
SCHEMBL9618341 0.83 CA12 (0.65) CA12CA9APEX1MEN1KMT2A
SCHEMBL16432726 0.77 CA12 (0.53) CA12CA9MEN1KMT2AHDAC3
SCHEMBL15486077 0.77 KDM4E (0.55) CA12CA9MEN1KMT2AKDM4E
SCHEMBL10826562 0.76 CA12 (0.45) CA12CA9APEX1MEN1KMT2A
SCHEMBL2993397 0.75 CA12 (0.41) CA12CA9MEN1KMT2ACDC25A
SCHEMBL5087842 0.73 MEN1 (0.55) CA12CA9MEN1KMT2A
SCHEMBL12311066 0.73 MEN1 (0.69) CA12CA9MEN1KMT2A
SCHEMBL27673616 0.72 KDM4E (0.42) CA12CA9APEX1MEN1KMT2A
SCHEMBL13444611 0.72 CA12 (0.47) CA12CA9APEX1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846939-B2 Salts and mixture of 9-oxoacridine-10-acetic acid with 1-alkylamino-1-desoxy-polyols, pharmaceutical compositions containing said agents and treatment methods EPHAG AS (EE) 2010-12-07 US disclosed
EP-1970372-B1 SALTS OF 9-OXOACRIDINE-10-ACETIC ACID WITH 1-ALKYLAMNO-1-DESOXY-POLYOLS EPHAG AS (EE) 2010-11-03 EP disclosed
US-20100144780-A1 Salts and Mixture of 9-Oxoacridine-10-Acetic Acid with 1-Alkylamino-1-Desoxy-Polyols, Pharmaceutical Compositions Containing Said Agents and Treatment Methods PJSC PHARMSYNTHEZ (RU) 2010-06-10 US disclosed
WO-2008121029-A2 USE OF 9-OXOACRIDINE-10-ACETIC ACID AND/OR SALTS AND/OR ITS ESTERS THEREOF FOR THE TREATMENT AND PROPHYLAXIS OF MALIGNANT TUMORS OF FEMALE REPRODUCTIVE SYSTEM SURKOV KIRILL GENNEDIEVICH (RU) 2008-10-09 WO disclosed
EP-1970372-A2 SALTS OF 9-OXOACRIDINE-10-ACETIC ACID WITH 1-ALKYLAMNO-1-DESOXY-POLYOLS EPhaG AS (EE) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144780-A1 Salts and Mixture of 9-Oxoacridine-10-Acetic Acid with 1-Alkylamino-1-Desoxy-Polyols, Pharmaceutical Compositions Containing Said Agents and Treatment Methods ADSL, ACMSD, ASS1 CA12 823/4885CA9 42/4885APEX1 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.